Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Keros Therapeutics, Inc. (NASDAQ: KROS) announced that CEO Jasbir S. Seehra, Ph.D. will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 9:20 am ET. The presentation will be available via live webcast and will be archived on Keros’ investors' page for 90 days post-event. Keros specializes in developing treatments for hematological and musculoskeletal disorders, focusing on unmet medical needs with candidates like KER-050 for cytopenias, KER-047 for iron imbalance-related anemia, and KER-012 for bone loss disorders.

LEXINGTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the 11^th Annual SVB Leerink Global Healthcare Conference on Friday, February 18th at 9:20 am ET.

The fireside chat presentation will be webcast live at https://wsw.com/webcast/svbleerink67/register.aspx?conf=svbleerink67&page=kros&url=https://wsw.com/webcast/svbleerink67/kros/2687550 and archived in the Investors section of the Keros website at https://ir.kerostx.com/. A replay will be available for 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros’ third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Investor Contact:
Mike Biega
mbiega@soleburytrout.com
617-221-9660

FAQ

When is Keros Therapeutics' presentation at the SVB Leerink Global Healthcare Conference?

Keros Therapeutics will present on February 18, 2022, at 9:20 am ET.

Who is presenting for Keros Therapeutics at the conference?

Keros Therapeutics' CEO Jasbir S. Seehra, Ph.D. will present.

Where can I watch the Keros Therapeutics presentation?

The presentation can be watched live via webcast and will be archived on Keros' investors' website.

What are Keros Therapeutics' main product candidates?

Keros Therapeutics is developing KER-050 for cytopenias, KER-047 for anemia from iron imbalance, and KER-012 for bone loss disorders.

What does Keros Therapeutics focus on?

Keros Therapeutics focuses on novel treatments for hematological and musculoskeletal disorders with high unmet medical need.